Gut Microbiota Market Analysis

  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Gut Microbiota Market Analysis

Application (Therapeutics, Diagnostics)

The global gut microbiota market is segmented and analyzed for demand and supply by application into therapeutics, and diagnostics. Out of the two types of gut microbiota, the segment is estimated to gain the largest market share of about 60% in the year 2037. The growth of the segment can be attributed to the increasing expenditure on biomedical, biopharmaceutical as well as biotechnology industries worldwide as well as increasing sales of biopharmaceuticals post-COVID -19. For instance, out of the total drug sales in 2021, biopharmaceuticals generated around 40% of global drug sales. Furthermore, the rising number of collaborations for R&D between market key players to better understand human gut health and develop apparent drug delivery systems to enhance the balance of gut microbiota besides the growing technological advancement in the therapeutics segment is further anticipated to boost the segment growth.

Disease (Autoimmune Disorder, Gastrointestinal Disorder, Infectious)

The global gut microbiota market is also segmented and analyzed for demand and supply by disease into autoimmune disorders, gastrointestinal disorders, infectious and others. Amongst these three segments, the infectious segment is expected to garner a significant share of around 45% in the year 2037. The segment growth is backed by the increasing prevalence of unspecified gastroenteritis as well as the growing number of suffering from patient diarrheal illnesses besides rising incident cases of acute gastrointestinal (GI) infections caused by Campylobacter, nontyphoidal Salmonella, Shigella, Escherichia coli (E. coli), or norovirus. For instance, a report stated that between the years 2010-2019, in the United States, the cases of unspecified gastroenteritis/diarrhea diagnoses accounted for over 98%. Moreover, nearly 2,241 cases of Campylobacter infections were diagnosed in the same period followed by Salmonella infections, Shigella, Escherichia coli (E. coli), or norovirus.

Our in-depth analysis of the global market includes the following segments:

              By Product

  • Probiotics
  • Prebiotics
  • Supplements
  • Drugs
  • Foods
  • Others

           By Application

  • Therapeutics
  • Diagnostics

            By Disease

  • Autoimmune Disorder
  • Gastrointestinal Disorder
  • Infectious
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gut microbiota is estimated at USD 1.02 billion.

The gut microbiota market size was over USD 770.87 million in 2024 and is anticipated to cross USD 7.56 billion by 2037, growing at more than 19.2% CAGR during the forecast period i.e., between 2025-2037. The increasing focus on gut health and the immunity system post-pandemic as well as the rising prevalence of digestive illness coupled with chronic diseases will boost the market growth.

North America industry is set to hold largest revenue share of 35% by 2037, led by rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders.

The major players in the market are Merck KGaA, Metabiomics Corporation, ViThera Pharmaceuticals, Inc., Second Genome Inc., Microbiome Therapeutics LLC, Vedanta Biosciences, Inc., Osel, Inc., Synthetic Biologics, Inc., Synlogic, 4D Pharma plc, Metabogen AB, Symbiotix Biotherapies, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample